×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Patient Experience Data: How Could this Data Enhance Decision-Making at Different Stages of Medical Product Development?
Session Chair(s)
Meghana Chalasani, MHA
Lead, Advisory Committees, Office of New Drugs, CDER
FDA, United States
This forum will provide an opportunity for key stakeholders to discuss examples of various types of patient experience data, and how this data could potentially inform decision-making at different stages of medical product development.
Learning Objective : Define patient experience data; Describe types of patient experience data that could inform medical product development; Discuss how patient experience data can inform decision making at different stages of medical product development.
Speaker(s)
FDA Perspective
Michelle Campbell, PhD
FDA, United States
Associate Director, Stakeholder Engagement and Clinical Outcomes, ON, OND, CDER
Panelist
Elizabeth Hart, MD
FDA, United States
Branch Chief, General Medicine 1, OTAT, CBER
Panelist
Isabelle Lousada, MA
Amyloidosis Research Consortium, United States
Chief Executive Officer and President
Panelist
Kristina Bowyer
Ionis Pharmaceuticals, Inc., United States
Vice President, Patient Advocacy & Engagement
Have an account?